SAN DIEGO -- Volcano Corporation (NASDAQ: VOLC) today announced it has received clearance to market the PrimeWire PRESTIGE® pressure guide wire in Japan. In addition to accurately measuring intravascular pressure via Fractional Flow Reserve (FFR), the PrimeWire PRESTIGE® pressure guide wire delivers superior handling with a frontline tip design, enhanced torque and more support.
"Japanese physicians are global leaders in advanced guide wire techniques and truly appreciate a wire that handles well in complex patient anatomy," said Junichi Osawa, President and Managing Director of Volcano Japan. "Reduced coil spacing at the tip of the PrimeWire PRESTIGE® pressure guide wire improves tactile feel of the wire, allowing physicians to maneuver the wire easily. Physicians in the United States and Europe have strongly embraced the PrimeWire PRESTIGE® pressure guide wire because of its handling."
The PrimeWire PRESTIGE® pressure guide wire has a 90 percent improvement in torque compared to the SmartWire® II pressure guide wire. A larger core wire and SlyDx(TM) coating enabled improved trackability and smooth device delivery over the wire. Full market release of PrimeWire PRESTIGE® pressure guide wire in Japan is expected in the second quarter of 2011.
About Fractional Flow Reserve (FFR)
FFR is a guide wire based technology that measures blood pressure differences across lesions. FFR provides valuable information to physicians about lesion significance, allowing them to make important treatment decisions. Additionally, FFR guided therapy improves patient outcomes reducing the risk of death & heart attack by 34 percent.
About Volcano Corporation
Volcano Corporation (NASDAQ: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information, using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.
SOURCE Volcano Corporation
CONTACT: Edrienne Brandon of Volcano Corporation, +1-858-720-4136, firstname.lastname@example.org
Web Site: www.volcanocorp.com